SCHEMBL6313154

SCHEMBL6313154

COc1cc([N+](=O)[O-])ccc1OCCN1CCN(C)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
KDM4E B2RXH2 2/20 0.56
TDP1 Q9NUW8 1/20 0.54
HPGD P15428 2/20 0.51
MAPT P10636 2/20 0.50
NPC1 O15118 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
RAB9A P51151 1/20 0.50
MCHR1 Q99705 1/20 0.49
LMNA P02545 2/20 0.48
LTA4H P09960 2/20 0.47
KCNJ1 P48048 1/20 0.47
KCNH2 Q12809 1/20 0.47
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12448363 0.94 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL5381777 0.91 LTA4H (0.54) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL264564 0.91 LTA4H (0.57) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL5105861 0.89 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL2086647 0.88 KMT2A (0.61) ALDH1A1SMN1; SMN2KDM4ETDP1MAPT
SCHEMBL3863267 0.87 KDM4E (0.53) ALDH1A1SMN1; SMN2KDM4EHPGDMAPT
SCHEMBL1929880 0.86 LTA4H (0.57) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL15244401 0.86 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2KDM4ETDP1MAPT
SCHEMBL15567831 0.86 ALDH1A1 (0.69) ALDH1A1SMN1; SMN2KDM4ETDP1HPGD
SCHEMBL10036149 0.86 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2KDM4ETDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939874-B2 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. (US) 2005-09-06 US disclosed
EP-1427421-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS Amgen Inc. (US) 2004-06-16 EP disclosed
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use AMGEN INC. 2004-04-01 US disclosed
WO-2003018021-A1 2,4-DISUBSTITUTED PYRIMIDINYL DERIVATIVES FOR USE AS ANTICANCER AGENTS AMGEN INC. (US) 2003-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063705-A1 Substituted pyrimidinyl derivatives and methods of use DPYD, TYMP, TPMT ALDH1A1 433/4885SMN1; SMN2 1697/4885KDM4E 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.